|
No. |
Project title |
Source of finding |
years |
|
1 |
Anti-atherosclerotic Effects of Prostacyclin Analogues |
The Wellcome Research Laboratories, UK |
1983 |
|
2 |
Direct Assessment of Potential Anti-Atherosclerotic Drugs Using Human Atherosclerotic Cells |
Knoll AG, Germany |
1986 |
|
3 |
Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Mevinolin Using Human Aortic Cells (Two Parameters) |
Merck Sharp & Dome Co., USA |
1987 |
|
4 |
Use of Ex Vivo Cellular Model for the Study of MEVINOLIN Monotherapy Effect on Blood Serum Atherogenicity |
Merck Sharp & Dome Co. |
1989 |
|
5 |
Direct Assessment of Anti-Atherosclerotic Effects of Drugs and Chemicals Using Human Aortic Cells |
Sandoz Ltd., Switzerland |
1989 |
|
6 |
Investigation of Captopril Atherosclerosis-Related Effects Using Primary Culture of Human Aortic Cells |
Squibb-Heyden Int., Germany |
1990 |
|
7 |
Study of the Effect of Celiprolol Monotherapy on Blood Serum Atherogenicity |
The Upjohn Company, USA |
1991 |
|
8 |
Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Perindoprilat Using Human Aortic Cells |
Les Laboratoires Servier, France |
1991 |
|
9 |
Study of the effect of Perindopril monotherapy on blood serum atherogenicity |
Les Laboratoires Servier, France |
1992 |
|
10 |
The Investigation of Direct Antiatherogenic (Preventive) and Antiatherosclerotic (Therapeutic) Effects of ACAT Inhibitors |
SmithKline Beecham Pharmaceuticals, UK |
1992 |
|
11 |
Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effect of Garlic Using Human Aortic Cells |
Lichtwer Pharma GmbH, Germany |
1992 |
|
12 |
Examination of Immunomodulation Properties of Garlic Powder |
Lichtwer Pharma GmbH, Germany |
1992 |
|
13 |
Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of the Drugs Using Human Aortic Cells |
Asta Medica AG, Sweden |
1993 |
|
14 |
In-Depth Investigation of Garlic Powder Extract Atherosclerosis-Related Effects |
Lichtwer Pharma GmbH, Germany |
1993 |
|
15 |
Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Lipostabil Using Human Aortic Cells In Vitro |
Phone-Poulenc Rorer GmbH, Germany |
1993 |
|
16 |
The In Vitro Investigation of Antiatherosclerotic Effect of Moxonidine |
Beiersdorf-Lilly GmbH, Germany |
1993 |
|
17 |
Investigation of atherogenicity of blood serum of patients treated with Lipostabil |
Phone-Poulenc Rorer GmbH, Germany |
1993 |
|
18 |
Use of Ex Vivo Cellular Model for the Study of Sapec Effect on Blood Serum Atherogenicity |
Lichtwer Pharma GmbH, Germany |
1994 |
|
19 |
The Ex Vivo Investigation of Antiatherosclerotic Effect of Lipostabil |
Phone-Poulenc Rorer GmbH, Germany |
1994 |
|
20 |
The in Vitro Investigation of Antiatherosclerotic and Antiatherogenic Effects of Amlodipine |
Pfizer International Pharmaceuticals, USA |
1994 |
|
21 |
Use of Ex Vivo Cellular Model for the Study of Amlodipine Effect on Blood Serum Atherogenicity |
Pfizer International Pharmaceuticals, USA |
1994 |
|
22 |
Role of modified low density lipoproteins and anti-lipoprotein antibodies in atherosclerosis development |
Russian Foundation of Basic Sciences , Russian Federation |
1994 |
|
23 |
The Study of Garlic Active Components Testing in In Vitro Cellular System |
Lichtwer Pharma GmbH |
1995 |
|
24 |
Anti-Atherosclerosis-Related Effects of Saterinone and BDF 9196 |
Beiersdorf-Lilly GmbH, Germany |
1995 |
|
25 |
Use of Ex-Vivo Cellular Model for the Study of Anti-Atherosclerosis-Related Effects of Amlodipine Plus Lovastatin Combination |
Pfizer International Pharmaceuticals, USA |
1995 |
|
26 |
Study of Allicor effect on coagulate system in patients with atherosclerosis and hypercoagulation I-II degree |
INAT-Farma Ltd., Russian Federation |
1996 |
|
27 |
Metabolism of multiple-modified low density lipoproteins in human aortic cells |
Russian Foundation of Basic Sciences , Russian Federation |
1997-1999 |
|
28 |
Study of Allicor glucose-lowering effect in diabetes mellitus type II (double blind placebo-controlled study) |
INAT-Farma Ltd., Russian Federation |
1998 |
|
29 |
Atherosclerosis monitoring and atherogenicity reduction (double blind placedo-controlled multi-center study |
INAT-Farma Ltd., Russian Federation |
1998-2003 |
|
30 |
Multicenter open prospective study of hypolipidemic efficacy and safety of oral use of Allicor in patients with moderate hyperlipidemia (phase III) |
INAT-Farma Ltd., Russian Federation |
2004-2005 |